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Introduction
Non-small-cell lung cancer (NSCLC) is the leading cause 
of cancer related death in the UK, with more than 
35 000 deaths annually.1 Accurate staging is fundamental 
for optimal patient outcomes, particularly identification 
of metastatic disease, because this typically dictates 
therapeutic strategy. At least 20% of patients who undergo 
curative lung surgery relapse with undiagnosed metastatic 
disease (so-called futile thoracotomy),2 indicating that the 
current approach to NSCLC staging is suboptimal. 
Staging pathways are complex, relying on high technology 
imaging platforms such as CT, PET-CT, and MRI. In 
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Summary
Background Whole-body magnetic resonance imaging (WB-MRI) could be an alternative to multi-modality staging of 
non-small-cell lung cancer (NSCLC), but its diagnostic accuracy, effect on staging times, number of tests needed, cost, 
and effect on treatment decisions are unknown. We aimed to prospectively compare the diagnostic accuracy and 
efficiency of WB-MRI-based staging pathways with standard pathways in NSCLC.
Methods The Streamline L trial was a prospective, multicentre trial done in 16 hospitals in England. Eligible patients 
were 18 years or older, with newly diagnosed NSCLC that was potentially radically treatable on diagnostic chest CT 
(defined as stage IIIb or less). Exclusion criteria were severe systemic disease, pregnancy, contraindications to MRI, 
or histologies other than NSCLC. Patients underwent WB-MRI, the result of which was withheld until standard 
staging investigations were complete and the first treatment decision made. The multidisciplinary team recorded its 
treatment decision based on standard investigations, then on the WB-MRI staging pathway (WB-MRI plus additional 
tests generated), and finally on all tests. The primary outcome was difference in per-patient sensitivity for metastases 
between standard and WB-MRI staging pathways against a consensus reference standard at 12 months, in the per-
protocol population. Secondary outcomes were difference in per-patient specificity for metastatic disease detection 
between standard and WB-MRI staging pathways, differences in treatment decisions, staging efficiency (time taken, 
test number, and costs) and per-organ sensitivity and specificity for metastases and per-patient agreement for local 
T and N stage. This trial is registered with the International Standard Randomised Controlled Trial registry, number 
ISRCTN50436483, and is complete.
Findings Between Feb 26, 2013, and Sept 5, 2016, 976 patients were screened for eligibility. 353 patients were recruited, 
187 of whom completed the trial; 52 (28%) had metastasis at baseline. Pathway sensitivity was 50% (95% CI 37–63) 
for WB-MRI and 54% (41–67) for standard pathways, a difference of 4% (–7 to 15, p=0·73). No adverse events related 
to imaging were reported. Specificity did not differ between WB-MRI (93% [88–96]) and standard pathways (95% 
[91–98], p=0·45). Agreement with the multidisciplinary team’s final treatment decision was 98% for WB-MRI and 
99% for the standard pathway. Time to complete staging was shorter for WB-MRI (13 days [12–14]) than for the 
standard pathway (19 days [17–21]); a 6-day (4–8) difference. The number of tests required was similar WB-MRI 
(one [1–1]) and standard pathways (one [1–2]). Mean per-patient costs were £317 (273–361) for WBI-MRI and £620 
(574–666) for standard pathways.
Interpretation WB-MRI staging pathways have similar accuracy to standard pathways, and reduce the staging time 
and costs.
Funding UK National Institute for Health Research.
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England, for example, the National Institute for Health 
and Care Excellence (NICE) publishes guidelines that 
require multiple, sequential imaging tests to complete 
staging and allow the first treatment decisions to be 
made.3,4 The complexity of staging pathways is due to 
modalities having variable accuracies across organs at 
risk for harbouring metastases. Standard pathways are, 
therefore, time and resource intensive, irradiate patients,5 
and increase anxiety if protracted.6
Modern MRI scanners can image the entire body within 
1 h, and whole-body MRI (WB-MRI)—which typically 
scans from the head to mid-thigh—is a potentially more 
accurate and safer alternative to standard multimodality 
staging pathways. WB-MRI could also accelerate staging, 
thereby increasing efficiency by reducing additional tests, 
staging time, and costs. Meta-analyses suggest accuracy of 
WB-MRI in detecting metastatic disease for metastatic 
disease is equivalent to, or might exceed, standard 
technologies,7–18 but most reports combine disparate 
cancers7–9,11,12,14,15 or those considering lung cancer alone 
focus on metastasis detection in a single organ, typically 
bone.10,13,16–18 Primary studies of WB-MRI in lung cancer 
staging are predominantly small, single site, explanatory 
studies with WB-MRI interpretation by a few highly 
experienced radiologists, which is unlike real-world 
pathways.4 Studies usually compare single modalities 
(eg, WB-MRI vs PET-CT) instead of the multiple staging 
tests encountered in daily practice.4 There are no data 
regarding how WB-MRI pathways influence staging times, 
additional tests, costs, or treatment decisions. As such, 
there is insufficient evidence to assess whether WB-MRI 
should be adopted.19
We did two parallel prospective multicentre trials to 
elucidate and directly compare the diagnostic accuracy 
and efficiency of WB-MRI-based staging pathways with 
standard staging in NSCLC (Streamline L) and colon 
cancer (Streamline C).20 Here, we report findings from 
Streamline L.
Methods
Study design and participants
Streamline L is a multicentre, prospective trial comparing 
diagnostic accuracy for metastatic disease of staging 
pathways based on initial WB-MRI, with standard staging 
in NSCLC. Ethics committee approval was granted on 
Oct 3, 2012, and the trial was coordinated by Cancer 
Research UK and University College London Cancer 
Trials Centre, with oversight from an independent data 
monitoring committee and a trial steering committee. 
All patients gave written informed consent.
Research in context
Evidence before this study
The detection of metastatic disease during non-small-cell lung 
cancer (NSCLC) staging underpins treatment strategy and is 
fundamental to optimisation of patient outcomes. Staging 
pathways rely on high technology imaging platforms such 
as CT, PET-CT, and MRI, which differ in their diagnostic 
accuracies across individual organs. Such multimodality staging 
pathways are complex, resource and time intensive, involve 
irradiation, and increase patient anxiety. Modern MRI platforms 
can image the whole body within 1 h, and whole-body MRI 
(WB-MRI) is advocated as a more accurate, efficient, and safer 
alternative to multimodality staging pathways. We searched 
PubMed and Embase (without language restriction) for articles 
published between Jan 1, 1990, and Sept 30, 2018, using MeSH 
and full-text search-strings for “cancer”, “neoplasm”, “staging”, 
“diagnostic accuracy”, “magnetic resonance imaging”, “whole 
body imaging”, “diffusion magnetic resonance imaging”, 
“metastasis”, and “lung”. We found several meta-analyses 
reporting WB-MRI accuracy for lung cancer staging, most 
suggesting accuracy for metastatic disease is equivalent to, or 
might exceed standard technologies. All such meta-analyses, 
however, were limited to metastasis detection in specific end 
organs, notably bone. Various comparators have been selected 
but the majority compare WB-MRI with PET-CT, and 
scintigraphy (in the case of bone metastasis). Most primary 
studies were small, single site, and explanatory, with WB-MRI 
interpreted by a few specialised radiologists. They focused on 
single modality comparisons rather than evaluating real-world, 
multimodality staging pathways. We found no data regarding 
how WB-MRI influences the first major treatment decision or 
staging efficiency.
Added value of this study
To our knowledge, this is the largest prospective multicentre 
trial to date comparing the diagnostic accuracy of WB-MRI 
staging pathways to standard staging in patients newly 
diagnosed with NSCLC. We used a pragmatic trial design to 
better test pathway performance in routine clinical practice and 
investigated staging pathway efficiency in terms of test number, 
time to completion, and costs. We also contemporaneously 
tested the effect of alternative staging pathways on the nature 
and timing of the first major treatment decisions. Patient 
outcomes were followed-up after 12 months to better evaluate 
pathway accuracy at the time of initial staging. We found both 
pathways had similar accuracies for identifying patients with 
metastatic disease and the nature of the first major treatment 
decision was similar. WB-MRI was more efficient and reduced 
the time to staging completion and costs.
Implications of all the available evidence
WB-MRI staging pathways have similar accuracy to current 
standard staging pathways, resulting in the same treatment 
decisions. However, they are more efficient and reduce time to 
complete staging and costs. WB-MRI is, therefore, more 
suitable for staging in routine clinical practice. Future research 
should investigate the utility of WB-MRI treatment response 
assessment and cancer surveillance after curative treatments.
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Patients were recruited from 16 general and teaching 
UK National Health Service (NHS) hospitals. Because 
11 of the 16 sites did not have the infrastructure to do 
WB-MRI, these sites sent patients to a nearby hospital 
for scanning (appendix p 2). Eligible patients were aged 
18 years or older with histologically proven or suspected 
NSCLC on chest CT, referred for staging. Suspicion of 
NSCLC was defined as an abnormality with CT 
characteristics sufficiently suggestive of NSCLC to 
indicate additional diagnostic and staging investigations. 
The disease had to be potentially radically treatable on 
the diagnostic CT chest, defined as stage IIIb or less 
(ie, T1–4, N0–2, and M0 by TNM 721). Patients were 
ineligible if further workup was considered inappropriate 
by the clinical care team or patient. Histologies other 
than non-small-cell were ultimately excluded, but 
patients undergoing treatment based on clinically 
diagnosed NSCLC remained eligible. Patients were 
ineligible if they could not provide informed consent, 
had severe systemic disease making it undesirable to 
participate, were pregnant, or had contraindications to 
MRI.
Participants were identified from outpatient clinics, 
multidisciplinary team meetings, and inpatient wards by 
local research team, who took informed consent from 
consecutive, unselected, eligible patients. A screening log 
detailed all patients approached and reasons for non-
participation, where applicable. Age, performance status, 
sex, and request date for the first staging investigation 
were collected from recruited patients. Staging completion 
date was also recorded, defined as the date of the final test 
in the standard staging pathway.
The protocol has been published4 and is available 
online.
Procedures
Participants had contemporaneous WB-MRI plus all 
standard staging investigations done as part of usual 
clinical care. Standard investigations were generally 
undertaken at the recruitment site, or a secondary 
hospital by referral in the case of specialised tests (such 
as PET-CT), and were interpreted by local consultant 
radiologists as per usual clinical practice. Interpretation 
of standard investigations was masked to WB-MRI 
images and findings. Case report forms included the 
nature and date of all standard investigations actually 
done before the first major treatment decision, and their 
findings regarding presence and location of metastatic 
disease.
The platform used for WB-MRI was in line with usual 
practice. A minimum dataset of sequences was acquired, 
including diffusion, T2-weighted, and T1-weighted (pre-
intravenous and post-intravenous gadolinium contrast 
medium) imaging (appendix p 3). WB-MRI datasets were 
uploaded electronically to a secure central imaging server 
(3Dnet; Biotronics3D, London, UK) for interpretation, 
and were withheld initially from the local Picture 
Archiving and Communications System to ensure local 
radiologists interpreting standard staging interventions 
were masked.
Across all recruitment sites and imaging hubs, 
16 radiologists interpreted WB-MRI and were unaware 
of all other standard staging investigations and clinical 
information (other than the suspected cancer diagnosis 
and its lobar location). All radiologists were fellows of 
the Royal College of Radiologists and had interpreted at 
least 20 validated staging WB-MRIs. Radiologists with 
experience of fewer than 100 WB-MRI datasets initially 
had their reports validated by more experienced 
colleagues (ie, had worked on >100 WB-MRI datasets) 
and reported alone only once deemed competent by 
their colleague. This procedure was designed specifically 
to mirror how WB-MRI would be reported in NHS 
practice if more widely disseminated. Radiologists 
completed case report forms documenting the T and 
N stage of the local tumour,21 and the presence, location, 
and diameter of metastatic disease across various 
anatomical sites using six numerical confidence levels 
grouped subsequently into normal, equivocal, and 
abnormal. Radiologists interpreted WB-MRI as per 
their usual practice, considering known morphology 
and characteristics of metastatic disease across the 
various MRI sequences,22 and reproduced case report 
form findings in a free text clinical report, uploaded 
onto the 3Dnet software for subsequent release to the 
multidisciplinary team meeting. If additional tests were 
recommended for equivocal findings, this suggestion 
was included in their report.
Patients were discussed in the multi-disciplinary team 
meeting at their local hospital as per usual care pathways. 
WB-MRI images and reports were withheld until patients 
had completed all standard staging investigations so that 
the multidisciplinary team made its first major treatment 
decision based only on standard staging.4 The decision 
was documented (appendix p 4), along with the TNM 
stage assigned.
In the same meeting, the WB-MRI report and images 
were then shown to the multidisciplinary team via 
3Dnet. The team considered the report and images and 
stated whether additional tests would have been 
requested before the first major treatment decision 
could be reached, had WB-MRI been the initial staging 
investigation (eg, to investigate equivocal findings). Any 
such tests were then done if they or an equivalent test 
had not already been done as part of the standard 
pathway and the multidisciplinary team considered 
them essential to patient care. If done already, their 
results were noted. The multidisciplinary team recorded 
the TNM stage based on the WB-MRI staging pathway 
(ie, WB-MRI plus the results of any additional tests 
generated, if any) and stated what the first major 
treatment decision would have been on the basis of this 
pathway. The final multidisciplinary team treatment 
decision was then made based on all available tests 
For the protocol see https://
www.ctc.ucl.ac.uk/TrialDetails.
aspx?Trial=90&TherA=7
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(ie, standard pathway, WB-MRI, and any additional tests; 
appendix p 4).
We devised a reference standard using multidisciplinary 
consensus panel review, a procedure that is standard for 
diagnostic test accuracy studies where an independent 
reference standard does not exist or is impossible 
because of incorporation bias.4,23 Patients were followed-
up for 12 months (or until death, if sooner). Each 
recruitment site convened a series of panels to derive the 
reference standard TNM stage, consisting of at least two 
radiologists (one external to the site) with expertise in 
cross-sectional imaging and nuclear medicine, and at 
least one of the following: respiratory physician, thoracic 
surgeon, or oncologist. The panel had access to a 
histopathologist if required, and a member of the Cancer 
Research UK and University College London Cancer 
Trials Centre and trial management group attended to 
ensure the consensus process was uniform across the 
trial. The panel considered all available clinical data over 
the follow-up period, including images and results of all 
staging and follow-up investigations, surgical findings, 
histopathology (surgical resections and biopsies), and 
patients’ clinical course, and assigned a TNM stage for 
the time of recruitment. The location and size of any 
metastatic deposits were recorded. In the absence of 
histological proof, metastatic disease was assumed if 
new lesions appeared during follow-up with suggestive 
imaging characteristics, or if compatible lesions that 
were already present either progressed or responded to 
therapy. Specific criteria were applied depending on 
length of follow up (in the case of death) and if the 
primary tumour remained in situ (appendix p 5). From 
all follow-up data, the panel assigned a retrospective 
optimal primary treatment decision, noting radiological 
perceptual errors in the initial interpretation of staging 
investigations (ie, unreported metastases that could be 
identified by the panel in retrospect, with full knowledge 
of all follow-up investigations).
Outcomes
The primary outcome was the difference in per-patient 
sensitivity for metastatic disease detection between 
standard and WB-MRI staging pathways, compared 
against the consensus reference standard. Prespecified 
outcomes were reported according to the diameter of the 
largest metastatic deposit (≥1 cm or <1 cm) to assess the 
effect of lesion size on diagnostic accuracy, per-organ 
sensitivity, and for WB-MRI as a stand-alone investigation 
based on the original radiologist report.
Secondary outcomes were difference in per-patient 
specificity for metastatic disease detection between 
standard and WB-MRI staging pathways, agreement 
between treatment decisions based on alternate pathways 
and the multidisciplinary team and consensus panel 
treatment decisions, staging efficiency (time taken, test 
number, and costs), per-organ sensitivity and specificity 
for metastasis, and per-patient agreement for local T and 
N stage. Additional secondary outcomes related to the 
effect of differing combinations of MRI sequences on 
accuracy, interobserver variability in WB-MRI inter-
pretation, and the effect of adding WB-MRI to standard 
pathways will be reported elsewhere. The comparative 
patient experience of staging pathways and the findings 
of a discrete choice experiment have already been 
reported.24–26
Statistical analysis
Using methods for comparative studies,27 we estimated 
that 50 patients with metastasis occult on diagnostic CT 
chest would give 80% power to detect a sensitivity 
difference of 24% between WB-MRI (79%) and standard 
pathways (55%), assuming 25% metastatic prevalence, 
53% concordance between pathways, and a 
20% withdrawal rate at 1 year, giving a target sample size 
of 250 patients. On Dec 7, 2015, as recommended by the 
independent data monitoring committee, the target 
sample size was revised to 353 patients to ensure 
inclusion of about 50 patients with metastasis.
We report our prespecified primary and secondary 
outcomes, and additional sensitivity analyses. Binary 
comparisons (sensitivity, specificity, and treatment 
decision agreement) were calculated using paired 
proportions (population marginal) in STATA 14.2 (College 
Station, TX, USA). For the primary outcome, equivocal 
disease was considered positive for metastasis. Sensitivity 
analysis treated equivocal results as negative.
There were no missing data for the primary outcome. 
Statistical significance was determined on the basis of 
95% CIs from Newcombe paired proportion method;28 
McNemar’s test p values are reported. Pathway treatment 
decisions were grouped for analysis (see appendix p 6) 
and compared to the final decisions made by the 
multidisciplinary team and consensus panel (as a 
sensitivity analysis). Time to complete staging pathways 
(excluding initial diagnostic tests) was calculated in days, 
by adding times for staging tests (from request to 
performance) to median wait times for a treatment 
decision by the multidisciplinary team, calculated across 
all patients. In the case of missing data, median times 
from the same or similar tests were used. The median 
difference in time and number of staging tests between 
pathways was compared for each patient with 95% CI 
from 2·5 and 97·5 centiles of 1999 bootstrap samples, 
with replacement used to compare between standard and 
WB-MRI staging pathways. Descriptive analysis of time 
to complete staging are reported in median days with 
IQR for staging pathways.
We compared the costs of WB-MRI versus standard 
pathways (appendix p 7). The cost analysis was based on a 
UK NHS perspective. Costs were calculated in pounds 
sterling (as of 2016–17) and were inflated as necessary. 
The time horizon was the time from initial diagnosis to 
treatment decision by the multidisciplinary team. Given 
the time horizon, which was less than 1 year, discounting 
Articles
www.thelancet.com/respiratory   Published online May 9, 2019   http://dx.doi.org/10.1016/S2213-2600(19)30090-6 5
was not applied. We calculated the mean cost per patient 
of tests received when undergoing standard imaging 
pathways only and WB-MRI (including additional staging 
tests ordered after the WB-MRI). We only included the 
cost of the tests received; the costs of the multidisciplinary 
team were not included because this cost was incurred 
irrespective of the type of staging test received. We did not 
include any adverse events related to imaging because no 
such events were reported. Unit costs were taken from 
2016–17 NHS reference costs.29 Decisions about which 
reference costs to use were made with appropriate clinical 
input (appendix pp 8–9). Mean per-patient staging costs 
for standard pathways and WB-MRI were compared 
using 95% CI derived from 1000 bootstrapped replications 
of the mean with replacement.
Streamline L is registered with the International 
Standard Randomised Controlled Trial registry, 
number ISRCTN50436483.
Role of the funding source
The funder of the study stipulated that the study design 
should be a diagnostic accuracy trial using a cohort 
design, but was not involved in data collection, data 
analysis, data interpretation, or writing of the report. The 
corresponding author had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
Between Feb 26, 2013, and Sept 5, 2016, 976 patients 
were screened for eligibility (figure 1). 353 patients 
were recruited, of whom 166 were excluded, mainly 
owing to a final diagnosis other than lung cancer 
(figure 1). The final cohort of 187 patients had a median 
age of 67 years (IQR 61–75) and 70 (37%) were women 
(figure 1, table 1). According to the consensus reference 
standard, 137 (73%) patients were stage T2 or above, 
77 (41%) were node-positive (appendix p 10), and 
52 (28%) had metastatic disease at the time of staging 
(appendix p 11), meeting sample size stipulations. In 
eight patients with metastatic disease at the time of 
staging (according to protocol definitions, appendix 
p 5), metastasis only became apparent during follow-up 
Figure 1: Trial profile
NSCLC=non-small-cell lung cancer. WB-MRI=whole-body MRI.
976 patients screened
623 excluded
 113 evidence of severe or uncontrolled 
 systemic disease
 110 unequivocal metastatic or N3 disease
 86 refused extra visit
 62 patients felt inclusion in the trial 
 would delay potential treatment
 53 histology other than NSCLC
 52 refused WB-MRI scan
 47 contraindications to WB-MRI
 29 site error or missed opportunity
 27 further staging workup not indicated
 20 too frail or not fit enough
 14 language barrier
 10 psychiatric or other condition
353 recruited
166 withdrawals
 84 no NSCLC diagnosis
 75 did not undergo WB-MRI
 4 withdrew consent
 1 lost to follow-up
 1 early release of WB-MRI findings
 1 died
187 assigned to pathway
WB-MRI pathway
187 had WB-MRI, plus additional tests as required
Standard pathway
187 had standard tests
Reference standard
187 included in consensus panel at 12 months
Value
Sex
Male 117 (63%)
Female 70 (37%)
Age, years
Median (IQR) 67 (61–75)
Range 37–96
Performance status
Fully active 86 (46%)
Ambulatory
Able to work 75 (40%)
Not able to work 8 (4%)
Not recorded 18 (10%)
Tumour location*
Right upper lobe 73 (39%)
Right middle lobe 14 (7%)
Right lower lobe 24 (13%)
Left upper lobe† 54 (29%)
Left lower lobe 28 (15%)
Histological subtype
Adenocarcinoma 115 (62%)
Large cell 4 (2%)
Squamous 42 (22%)
Adenosquamous 1 (1%)
Other 13 (7%)
No histology or missing 12 (6%)
Data are n (%) unless otherwise stated. *By consensus reference standard. Some 
patients have multiple tumour locations. †Including the lingula.
Table 1: Baseline characteristics of final trial cohort
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and was not visible on initial staging investigations, 
even in retrospect.
Sensitivity of staging for patients with metastatic 
disease was 50% (95% CI 37–63) for WB-MRI and 54% 
(41–67) for standard pathways, a difference of 4% (–7 to 15, 
p=0·73; figure 2, table 2). For the primary outcome, there 
were seven perceptual errors in the WB-MRI pathway 
and three in the standard pathway. No adverse events 
(serious or non-serious) were reported during the trial.
Specificity did not differ between the WB-MRI pathway 
(93% [88–96]) and standard pathway (95% [91–98], 
p=0·45). The number of equivocal results per pathway is 
shown in the appendix (p 12). Sensitivity analysis found 
no differences between pathways when lesions reported 
as equivocal were treated as either all positive or all 
negative (table 2), or across individual organ sites 
(appendix p 13). The WB-MRI pathway had 82% (64–92) 
sensitivity for patients whose largest metastasis was at 
least 1 cm, which did not differ from standard pathways 
(75% [57–87]); for those with metastasis smaller than 
1  cm, sensitivity was 9% (3–28; appendix p 14). As a 
stand-alone investigation (ie, without additional tests 
generated), WB-MRI had a similar sensitivity to that of 
the standard pathway, but had lower specificity than the 
standard pathway (appendix p 15).
The WB-MRI pathway had 65% agreement for N stage 
compared with 75% for the standard pathway, a 
significant difference of 10% (3–18; appendix p 16). Of 
the 187 patients, 109 had histological proof of N stage, 
usually via endobronchial ultrasound nodal sampling or 
surgery, or both. In these patients, there remained a 
difference in agreement of 10% (1–19) between WB-MRI 
and standard pathways (appendix p 17). Pathways did not 
significantly differ in terms of agreement for T stage 
(appendix p 18).
Agreement with the final treatment decision of the 
multidisciplinary team was 98% for WB-MRI and 99% 
for the standard pathway (table 3). Treatment decisions 
based on WB-MRI and standard pathways had similar 
levels of agreement with the retrospective consensus 
panel optimal treatment decision (appendix p 19).
Across the cohort, standard staging pathways involved 
302 individual investigations and WB-MRI involved 
232 individual investigations; WB-MRI pathways 
generated an additional 45 tests (appendix pp 20–21). 
The median number of tests did not differ between the 
WB-MRI (one [1 to 1]) and standard (one [1 to 2]) 
pathways (difference 0 [–1 to 0]; appendix p 22).
Time to staging was shorter for WB-MRI pathways 
than for standard pathways (13 days [12–14] vs 19 days 
[17–21]); a difference of 6 days (4–8) (figure 3, appendix 
pp 23–24). Mean per-patient costs for the WB MRI 
pathway (£317 [273–361]) were lower than for the standard 
staging pathway (£620 [574–666]; appendix p 25).
Discussion
To date, Streamline L is the largest prospective multi-
centre trial to compare the diagnostic accuracy of 
WB-MRI and standard staging pathways for metastatic 
disease in patients with newly diagnosed NSCLC. Both 
pathways showed similar accuracy, but the WB-MRI 
pathway was more time-efficient and cost-efficient. 
Treatment decisions were similar. Our data suggest 
WB-MRI is a viable replacement for standard pathways.
WB-MRI pathways had no advantage over standard 
pathways in terms of diagnostic accuracy. The overall 
Figure 2: WB-MRI and standard staging pathways sensitivity and specificity for patients with metastatic disease against the consensus reference standard
WB-MRI=whole-body MRI.
A True
positive
False
negative
True
negative
False 
positive
Sensitivity 
(95% CI)
WB-MRI
Standard
26
28
26
24
9
6
126
129
50% (37–63)
54% (41–67)
200 10040 60 80
Sensitivity (%)
B Specificity 
(95% CI)
93% (88–96)
95% (91–98)
200 10040 60 80
Specificity (%)
  
Patients with 
metastatic 
disease*
Sensitivity Patients without 
metastatic 
disease*
Specificity
WB-MRI 
staging 
pathway†
Standard 
staging 
pathway
Difference p value WB-MRI 
staging 
pathway†
Standard 
staging 
pathway
Difference p value
Diagnostic accuracy 52 50% 
(37 to 63)
54% 
(41 to 67)
–4% 
(–15 to 7)
p=0·73 135 93% 
(88 to 96)
95% 
(91 to 98)
–2% 
(–7 to 2)
p=0·45
Equivocal lesions 
considered negative
52 48% 
(35 to 61)
46% 
(33 to 59)
2% 
(–11 to 14)
·· 135 94% 
(89 to 97)
97% 
(93 to 99)
–3% 
(–6 to 1)
··
Data are n or % (95% CI). *Patients by consensus reference standard. †WB-MRI plus additional generated tests.
Table 2: Per-patient sensitivity and specificity for metastatic disease
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sensitivity of both pathways for metastatic disease was 
lower than published studies10,13 suggest, although 
2018 data30 challenges the accuracy of standard staging 
pathways. We excluded patients with locally advanced or 
metastatic disease on their diagnostic CT chest (including 
the lower neck, liver, and adrenal glands) because these 
patients generally undergo treatment without curative 
intent. Such exclusion is unusual in the literature. 
Metastases were therefore either occult or involved 
remote sites. Eight patients developed their first 
metastasis during follow-up which were not visible in 
retrospect on any staging examination. The concept of 
occult metastatic disease is well established: 35% of 
patients develop metastatic disease post thoracotomy 
despite a negative staging PET-CT.31 The number of 
perceptual errors was low, and many retrospectively 
visible lesions were subtle and difficult to detect 
prospectively. As a pragmatic trial, Streamline L provides 
the best estimate of NSCLC staging accuracy in routine 
clinical practice.
We found that the WB-MRI pathway had 82% sensitivity 
for patients with metastatic disease of at least 1 cm, 
compared with only 9% for smaller metastasis. Our 
WB-MRI protocol complied with accepted international 
standards,32 including diffusion weighted imaging and 
post-gadolinium sequences; however, by necessity, had to 
compromise—for example, on slice thickness—to 
ensure reasonable total scan times. The previous largest 
study of WB-MRI was a single site comparison with 
PET-CT alone,22 which reported WB-MRI had a per-
patient sensitivity of 70% and specificity of 92%, 
compared with 63% and 95% for PET CT, respectively. 
However, unlike Streamline L, imaging interpretation 
was done via the consensus of two experienced readers, 
and complete staging pathways were not evaluated. The 
effect on treatment decisions was not considered.
We found WB-MRI pathways had similar accuracy for 
T staging compared with standard pathways, suggesting 
the anatomical information given by WB-MRI matched 
that of standard imaging. Sensitivities for N stage were 
comparable to that previously reported,17,18 but standard 
pathways were superior overall and in those with 
histological proof of N stage. It is widely accepted that 
invasive nodal staging with endobronchial ultrasound 
(and EUS where available) is superior to imaging 
techniques for detecting nodal metastases33 and current 
guidelines recommend sampling of enlarged mediastinal 
nodes if it would affect patient management.34 We 
specifically investigated implementation of WB-MRI 
after diagnostic CT, which was therefore also available for 
lymph node size measurement as part of the clinical 
decision making for this pathway. The 2019 NICE 
guidelines35 recommend a systematic approach to staging 
hilar and mediastinal nodes with increased use of 
endobronchial ultrasound-guided sampling. Endo-
bronchial ultrasound was available to all Streamline L 
recruitment sites as part of patient diagnostic and staging 
workup. The lower sensitivity of WB-MRI for nodal 
staging will likely be offset by  the current invasive 
approach to N staging if status affects treatment 
decisions. Furthermore, nodal stage alone does not 
dictate treatment; for example, patients staged N0, N1, 
and, in some cases, N2 disease are still candidates for 
surgery, and patients with metastatic disease are treated 
accordingly, regardless of nodal stage. In support, the 
lower sensitivity of the WB-MRI pathway did not 
negatively affect treatment decisions. Agreement with 
both the final multidisciplinary team treatment decision 
and the optimal retrospective treatment decision was 
similar for both staging pathways, suggesting that 
WB-MRI could replace standard pathways without 
patient detriment.
Generally, efficiency receives less attention than 
diagnostic accuracy.19 Timeliness of lung cancer 
treatment is a care quality indicator; reducing time to 
treatment decisions by 2 weeks is associated with 
improved  survival33 and prolonged pathways increase 
patient anxiety.6 Streamline L found that WB-MRI 
pathways were more efficient than standard pathways, 
reducing the time to complete staging significantly and 
decreased average per-patient staging costs by £303, 
largely due to PET-CT use by standard pathways. 
n* WB-MRI staging pathway† Standard staging pathway Difference 
agreement, 
% (95% CI)
Agreement Disagreement Agreement Disagreement
All patients 183 180 (98%) 3 (2%) 181 (99%) 2 (1%) –1% (–4 to 2)
Patients with 
metastatic disease
52 51 (98%) 1 (2%) 50 (96%) 2 (4%) 2% (–7 to 11)
Patients without 
metastatic disease
131 129 (98%) 2 (2%) 131 (100%) 0 –2% (–4 to 1)
Data are n (%) unless otherwise stated. *Four patients were missing at least one type of patient treatment decision. 
†WB-MRI plus additional generated tests.
Table 3: Agreement between pathway and multidisciplinary team treatment decisions
Figure 3: Time taken for staging pathways
WB-MRI=whole-body MRI.
Median
days 
(95% CI)
All patients
WB-MRI
Standard
Patients with metastatic disease
WB-MRI
Standard
Patients without metastatic disease
WB-MRI
Standard
13 (12–14)
19 (17–21)
13 (11–15)
20 (16–23)
13 (11–14)
19 (16–21)
50 2510 15 20
Time taken (days)
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Efficiency of WB-MRI pathways could potentially 
increase given the growth of routine cranial imaging in 
staging, and the emphasis on oligometastatic (M1b) 
disease detection in the eighth edition of TNM. On 
average, the generation of additional tests to the WB-MRI 
pathway added 4–5 days to the pathway staging time. 
Although MRI access is restricted in many health-care 
settings, our data suggest that increased provision would 
ultimately reduce the cost and complexity of staging 
NSCLC. Although patients report that having WB-MRI is 
a greater burden than standard imaging,24 a discrete 
choice experiment26 done as part of the trial shows 
patients generally prefer WB-MRI staging to standard 
pathways if they reduce staging times and radiation 
exposure as found in Streamline L.
A strength of our trial is its pragmatic design. We 
recruited from a representative range of general and 
teaching hospitals, with all imaging done and interpreted 
according to usual local protocols, to increase general-
isability of our results. The 16 radiologists interpreting 
WB-MRI were representative of those who would do so 
in daily NHS practice. We avoided using a smaller 
number of highly experienced radiologists; although 
we acknowledge that such individuals might achieve 
sensitivities greater than we report, they do not represent 
the national workforce. We used multidisciplinary team 
meetings to mirror patient care in the NHS. In doing so, 
we captured the entirety of standard pathways, including 
contemporaneous treatment decisions. We used a novel 
cloud-based image repository to maintain blinding and 
control multidisciplinary team access to WB-MRI until 
the appropriate time in the decision-making process. We 
were able to model the content and timing of WB-MRI 
staging pathways, and the potential effect on decision 
making. Conversely, previous research usually reports 
head-to-head comparisons between single imaging 
platforms, failing to capture pathway complexity. To our 
knowledge, our trial design is unique.
Streamline L does have limitations. Our withdrawal rate 
was superficially high, but most excluded participants 
were excluded because of a final diagnosis other than 
NSCLC. We masked radiologists reporting WB-MRI to 
patient history and contemporaneous imaging. This was 
masked to isolate diagnostic test accuracy within a 
pragmatic setting. Participants were representative of 
those undergoing staging in daily practice, although we 
did exclude pregnant women, patients not wanting to 
undergo WB-MRI, and patients with contraindications to 
MRI. We modelled timing of WB-MRI staging pathways 
on the basis of real waiting times collated from recruitment 
sites during the trial, although sites had capacity to do 
WB-MRI. Waiting times might not be representative of 
those at other hospitals, and in other countries. Some of 
the benefits of reduced staging time by WB-MRI pathways 
could be negated if time to commencing treatment 
(eg, surgical resection) are not reduced in parallel. 
Treatment decisions based on WB-MRI pathways were 
made after the multidisciplinary team was unmasked to 
all standard imaging tests, which could introduce bias. 
However, this situation was unavoidable if the full 
complexity of standard staging pathways was to be 
captured without interference from WB-MRI findings 
and if treatment decisions were to be recorded 
contemporaneously. Furthermore, alternate pathway 
agreement with a retrospective optimal treatment at 
12 months remained very similar. Our cost analyses reflect 
an English NHS perspective and could differ in other 
settings, which might negate some of the cost advantages 
of WB-MRI pathways. Although WB-MRI is advocated as 
being safer than current standard staging investigations, 
new technologies are reducing radiation dose,36 and there 
are current uncertainties about the neuronal deposition of 
gadolinium.37 Further research is needed to define the 
potential use of WB-MRI in the assessment of treatment 
response and post-therapy surveillance for recurrent 
disease. Our findings are specific for NSCLC and might 
not be relevant to other primary tumour sites.
In summary, WB-MRI staging pathways have similar 
diagnostic accuracy to standard pathways for identifying 
patients with metastatic disease in newly diagnosed 
NSCLC, and lead to similar treatment decisions. 
However, they reduce staging time and costs. In a real-
world NHS setting, WB-MRI-based pathways are a viable 
replacement for standard pathways.
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